TrialMultiple sclerosis (Houndmills, Basingstoke, England)2025

Safety and tolerability of conversion to siponimod from other disease-modifying therapies in patients with advancing forms of relapsing MS: Results from the EXCHANGE study.

Robert J Fox et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.